Search hospitals > Ontario > BARRIE

Barrie GI Associates

Claim this profile
BARRIE, Ontario L4M 7G1
Conducts research for Crohn's Disease
Conducts research for Ulcerative Colitis
Conducts research for Colitis
Conducts research for Inflammatory Bowel Disease
Conducts research for Crohn's disease
10 reported clinical trials
0 medical researchers
Photo of Barrie GI Associates in BARRIEPhoto of Barrie GI Associates in BARRIEPhoto of Barrie GI Associates in BARRIE

Summary

Barrie GI Associates is a medical facility located in BARRIE, Ontario. This center is recognized for care of Crohn's Disease, Ulcerative Colitis, Colitis, Inflammatory Bowel Disease, Crohn's disease and other specialties. Barrie GI Associates is involved with conducting 10 clinical trials across 5 conditions. There are 0 research doctors associated with this hospital, such as .

Top PIs

Clinical Trials running at Barrie GI Associates

Ulcerative Colitis
Crohn's Disease
Colitis
Crohn's disease
Image of trial facility.

Risankizumab

for Ulcerative Colitis

Ulcerative colitis (UC) is a type of inflammatory bowel disease that causes inflammation and bleeding from the lining of the rectum and colon (large intestine).This study will evaluate how safe and effective risankizumab is compared to vedolizumab in treating adult participants with moderate to severe UC who are naive to targeted therapies (TaTs). Risankizumab and vedolizumab are approved medications for moderate to severe UC in multiple countries. Participants who meet the eligibility criteria will be randomized in a 1:1 ratio to receive open label risankizumab or vedolizumab. Approximately 530 adult participants with moderate to severe UC who are naïve to targeted therapies (TaTs) will be enrolled at 285 sites worldwide. For participants randomized to risankizumab, drug will be administered intravenous(IV) during the induction period followed by subcutaneous injection during the maintenance period. Participants randomized to vedolizumab will receive drug IV throughout the study. The duration of the study is approximately 69 weeks for participants randomized to risankizumab and 71 weeks for participants randomized to vedolizumab. This includes up to a 35-day screening period followed by a treatment period of 44 weeks for risankizumab and 46 weeks for vedolizumab. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular outpatient visits during the study. The effect and safety of the treatment will be checked by medical assessments, evaluation of side effects and completing questionnaires.
Recruiting2 awards Phase 31 criteria
Image of trial facility.

RO7790121

for Ulcerative Colitis

This Phase III, multicenter, double-blind, placebo-controlled study will evaluate the efficacy and safety of induction therapy with Afimkibart (RO7790121) compared with placebo in participants with moderately to severely active ulcerative colitis (UC).
Recruiting1 award Phase 34 criteria
Image of trial facility.

Icotrokinra

for Ulcerative Colitis

The purpose of this protocol is to evaluate the efficacy (how well it works), safety and tolerability of oral icotrokinra as therapy in adult and adolescent participants with moderately to severely active ulcerative colitis (UC, a chronic disease of the large intestine in which the lining of the colon becomes inflamed and develops tiny open ulcers).
Recruiting1 award Phase 35 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Barrie GI Associates?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security